190 related articles for article (PubMed ID: 14999555)
1. Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.
Gridelli C; Aapro M
Support Care Cancer; 2004 Jul; 12(7):487-96. PubMed ID: 14999555
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
Aapro M; Johnson J
Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
[TBL] [Abstract][Full Text] [Related]
3. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics.
Gridelli C
Drugs Aging; 2004; 21(13):825-32. PubMed ID: 15493948
[TBL] [Abstract][Full Text] [Related]
4. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
5. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
Aapro M
Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
[TBL] [Abstract][Full Text] [Related]
6. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
7. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
9. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
10. Medicinal plants as antiemetics in the treatment of cancer: a review.
Haniadka R; Popouri S; Palatty PL; Arora R; Baliga MS
Integr Cancer Ther; 2012 Mar; 11(1):18-28. PubMed ID: 21821652
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
12. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting.
Spitzer TR; Grunberg SM; Dicato MA
Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875
[TBL] [Abstract][Full Text] [Related]
14. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
15. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
16. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
19. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]